Participation of Patients From Racial, Ethnic Minority Groups in Phase 1 Cancer Drug Development Trials

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, NOVEMBER 3, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.30884?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110322

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: This study compared the proportions of racial and ethnic groups in 221 phase 1 clinical trials of drugs for metastatic cancer from 2000 to 2018 with population-based cancer registry data and found worsening disparities over time in the accrual of patients from racial and ethnic minority groups. These findings may represent widening inequalities in access to trial sites and worsening systemic biases. More efforts are needed to diversify phase 1 cancer drug trials to improve equity in access to new treatments and to ensure that safety and efficacy findings from early drug trials are generalizable across populations.

Authors: C. Jillian Tsai, M.D., Ph.D., of the Princess Margaret Cancer Centre in Toronto, is the corresponding author.

 

(doi:10.1001/jamanetworkopen.2022.30884)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.